Topic: neurodegenerative diseases
UB-312 prevented the accumulation of misfolded alpha-synuclein proteins in cell and animal models of Parkinson's disease.
The agreement covers small molecules designed to treat multiple neurodegenerative and systemic inflammatory diseases.
Protein clumps that occur in both the gut and the brain could be prime targets for Parkinson's therapies, new research suggests.
A Tufts University-led team has developed 3D models of the central nervous system that might prove useful for drug discovery.
Researchers accidentally reprogrammed mature neurons into dopamine-producing neurons—a discovery that could spark new therapies for brain diseases.
Swedish researchers have found that the rogue SOD1 protein can “transmit” protein misfolding in ALS.
The deal follows a midphase trial that linked oral myeloperoxidase inhibitor AZD3241 to numerical improvements on a scale of MSA symptoms.
Blocking the interaction between pathological tau proteins and the nuclear membrane of neurons could represent a new approach to Alzheimer's, a new study finds.
Gene therapy specialist RegenXBio has added another program to its pipeline, going after Batten disease variant CLN2.
Soluble toll-like receptors could hold promise in reversing amyloid plaques.